Abstract
Chemokines comprise a superfamily of at least 46 cytokines that were initially described based on their ability to bind to 18 to 22 G protein-coupled receptors to induce the directed migration of leukocytes to sites of inflammation or injury. In addition to mediating cellular migration, chemokine/chemokine receptor pairs have been shown to affect many cellular functions, including survival, adhesion, invasion, and proliferation, and to regulate circulating chemokine levels. Most malignancies also express one or more chemokine receptors. Early studies established a role for CXCR4 and CXCR7 in mediating breast cancer metastasis, but other chemokine receptors, including CXCR3, now are implicated in several malignancies as biomarkers of tumor behavior as well as potential therapeutic targets. This review summarizes our current understanding regarding the contribution of CXCR4 and CXCR3 to tumor behavior and how receptor expression is regulated, transduces intracellular signals, and contributes at the molecular level to tumor behavior. It also describes recent therapeutic approaches that target these receptors or their ligands.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Graham GJ, Nibbs RJ: Lukacs NW. Totowa, NJ: Humana Press; 2007:31–54.
Muller A, Homey B, Soto H, et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50–56.
Smith MCP, Luker KE, Gargow JR, et al.: CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004, 64:8604–8612.
Balkwill F: The significance of the cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 2004, 14:171–179.
Scotten CJ, Wilson JL, Scott K, et al.: Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002, 62:5930–5938.
Tamamura H, Hori A, Kanzaki N, et al.: T140 analogs as CXCR4 antagonists identified as antimetastatic agents in the treatment of breast cancer. FEBS Lett 2003, 550:79–83.
Bertolini F, Dell’Agnola C, Mancuso P, et al.: CXCR4 neutralization a novel therapeutic approach for non-Hodgkin’s lymphoma. Cancer Res 2002, 62:3106–3112.
Murakami T, Maki W, Cardones AR, et al.: Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 2002, 62:7328–7334.
Ben-Baruch A: Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis 2008, 25:345–356.
Zagzag D, Lukyanov Y, Lan L, et al.: Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 2006, 86:1221–1232.
Akashi T, Koizumi K, Nagakawa O, et al.: Androgen receptor negatively influences the expression of chemokine receptors (CXCR4, CCR1) and ligand-mediated migration in prostate cancer DU-145. Oncol Rep 2006, 16:831–836.
Sengupta S, Schiff R, Katzenellenbogen BS: Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER overexpressing, estrogen receptor-positive breast cancer cells. Breast Cancer Res Treat 2008 Sep 19 [Epub ahead of print].
Holland JD, Kochetkova M, Akekawatchai C, et al.: Differential functional activation of chemokine receptor CXCR4 is mediated by G proteins in breast cancer. Cancer Res 2006, 66:4117–4124.
Serrati S, Margheri F, Fibbi G, et al.: Endothelial cells and normal breast epithelial cells enhance invasion of breast carcinoma cells by CXCR4-dependent up-regulation of urokinase-type plasminogen activator receptor (uPAR, CD87) expression. J Pathol 2008, 214:545–554.
Akekawtchai C, Holland JD, Kochetkova M, et al.: Transactivation of CXCR4 by the insulin-like growth factor-1 receptor (IGF-1R) in human MDA-MB-231 breast cancer epithelial cells. J Biol Chem 2005, 280:39701–39708.
Chinni SR, Yamamoto H, Dong Z, et al.: CXC12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol Cancer Res 2008, 6:446–457.
Liang Z, Wu T, Lou H, et al.: Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res 2004, 64:4302–4308.
Yoon Y, Liang Z, Zhang X, et al.: CXC chemokine receptor-4-antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res 2007, 15:7518–7524.
Rubin JB, Kung AL, Klein RS, et al.: A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A 2003, 100:13513–13518.
Yang L, Jackson E, Woerner BM, et al.: Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res 2007, 67:651–658.
Kim SY, Lee CH, Midura BV, et al.: Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis 2008, 25:201–211.
Lasagni L, Francalanci M, Annunziato F, et al.: An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003, 197:1537–1549.
Ehlert JE, Addison CA, Burdick MD, et al.: Identification and partial characterization of a variant of human CXR3 generated by posttranscriptional exon skipping. J Immunol 2004, 173:6234–6240.
Monteagudo C, Martin JM, Jorda E, Llombart-Bosch A: CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathologic prognostic factors. J Clin Pathol 2007, 60:596–599.
Kawada K, Hosogi H, Sonoshita M, et al.: Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene 2007, 26:4679–4688.
Ma X, Norsworthy K, Kundu N, et al.: CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol Cancer Ther, in press.
Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM: The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood 2000, 95:627–632.
Klatte T, Seligson DB, Leppert JT, et al.: The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. J Urol 2008, 179:61–66.
Kawada K, Sonoshita M, Sakashita H: Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 2004, 64:4010–4017.
Goldberg-Bittman L, Neumark E, Sagi-Assif O, et al.: The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. Immunol Lett 2004, 92:171–178.
Goldberg-Bittman L, Sagi-Assif O, Meshel T, et al.: Cellular characteristics of neuroblastoma cells: regulation by the ELR-CXC chemokine CXCL10 and expression of a CXCR3-like receptor. Cytokine 2005, 29:105–117.
Datta D, Flaxenburg JA, Laxmanan S, et al.: Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res 2006, 66:9509–9518.
Walser TC, Rifat S, Ma X, et al.: Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res 2006, 66:7701–7707.
Zipin-Roitman A, Meshel T, Sagi-Assif O, et al.: CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res 2007, 67:3396–3405.
Luster AD, Leder P: IP-10, a C-X-C chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 1993, 178:1057–1065.
Sgadari C, Angiolillo AL, Cherney BW, et al.: Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci U S A 1996, 93:13791–13796.
Dorsey R, Kundu N, Yang Q, et al.: Immunotherapy with interleukin-10 depends on the CXC chemokines inducible protein-10 and monokine induced by IFN-gamma. Cancer Res 2002, 62:2606–2610.
Walser TC, Ma X, Kundu N, et al.: Immune-mediated modulation of breast cancer growth and metastasis by the chemokine Mig (CXCL9) in a murine model. J Immunother 2007, 30:490–498.
Winter D, Moser J, Kriehuber E, et al.: Down-modulation of CXCR3 surface expression and function in CD8+ T cells from cutaneous T cell lymphoma patients. J Immunol 2007, 179:4272–4282.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fulton, A.M. The chemokine receptors CXCR4 and CXCR3 in cancer. Curr Oncol Rep 11, 125–131 (2009). https://doi.org/10.1007/s11912-009-0019-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11912-009-0019-1